Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
19 sept. 2024 09h45 HE
|
Bavarian Nordic A/S
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger...
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
19 sept. 2024 09h45 HE
|
Bavarian Nordic A/S
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger...
Gavi indgår aftale med Bavarian Nordic for at sikre hurtig levering af 500.000 doser mpox-vaccine til Afrika
18 sept. 2024 04h45 HE
|
Bavarian Nordic A/S
Forhåndskøbsaftalen vil blive finansieret af Gavi’s First Response Fund, som blev etableret efter COVID-19-pandemien med henblik på at sikre hurtig adgang til knappe vaccineforsyninger i fremtidige...
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
18 sept. 2024 04h45 HE
|
Bavarian Nordic A/S
The advance purchase agreement (APA) will be funded by Gavi’s First Response Fund, a mechanism created after the COVID-19 pandemic to ensure rapid access to scarce vaccine supplies in future health...
Le seul vaccin contre le choléra à dose unique au Canada est disponible dans tout le pays
17 sept. 2024 11h01 HE
|
Bavarian Nordic A/S
TORONTO, 17 sept. 2024 (GLOBE NEWSWIRE) -- Bavarian Nordic, l’un des principaux fournisseurs mondiaux de vaccins pour voyageurs, a annoncé aujourd’hui la disponibilité commerciale de VAXCHORA®, le...
Canada's Only Single-Dose Cholera Vaccine Available Nationwide
16 sept. 2024 08h00 HE
|
Bavarian Nordic A/S
Bavarian Nordic announces availability of VAXCHORA, Canada's only single-dose cholera vaccine for travelers (age 2 to 64) to cholera-affected countries.
Bavarian Nordics mpox vaccine opnår prækvalifikation hos WHO
13 sept. 2024 05h57 HE
|
Bavarian Nordic A/S
Første mpox-vaccine, der opnår prækvalifikation hos WHOGodkendelsen vil hjælpe med at fremskynde adgangen til vaccinen i alle afrikanske lande KØBENHAVN, Danmark, 13. september 2024 – Bavarian...
Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine
13 sept. 2024 05h57 HE
|
Bavarian Nordic A/S
First mpox vaccine to obtain prequalification by the WHOApproval will help accelerate access to the vaccine for all African countries COPENHAGEN, Denmark, September 13, 2024 – Bavarian...
Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation
12 sept. 2024 04h54 HE
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, September 12, 2024 – Bavarian Nordic A/S (OMX: BAVA), the vaccine manufacturer of MVA-BN®, the only approved non-replicating smallpox and mpox vaccine (marketed as JYNNEOS®,...
Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation
12 sept. 2024 04h54 HE
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, September 12, 2024 – Bavarian Nordic A/S (OMX: BAVA), the vaccine manufacturer of MVA-BN®, the only approved non-replicating smallpox and mpox vaccine (marketed as JYNNEOS®,...